Richardson, Gary

Open-Label Phase III Trial of Panitumumab plus Best Supportive Care Compared with Best Supportive Care Alone in Patients with Chemotherapy-Refractory Metastatic Colorectal Cancer

Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 1,979

Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2

Monk, B. J., Poveda, A., Vergote, I., Raspagliesi, F., Fujiwara, K., Bae, D.-S., Oaknin, A., Ray-Coquard, I., Provencher, D. M., Karlan, B. Y., et al. (2016) · Gynecologic Oncology

Ovarian cancer diagnosis and treatmentPARP inhibition in cancer therapy

Cited by 98

Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation

Ruan, D.-Y., Wu, H.-X., Xu, Y., Munster, P. N., Deng, Y., Richardson, G., Yan, D., Lee, M.-A., Lee, K.-W., Pan, H., et al. (2025) · Signal Transduction and Targeted Therapy

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 22

Safety and efficacy of D-1553 in KRAS G12C-mutated colorectal cancer: Results from a phase I/II study.

Ruan, D.-Y., Lee, M. A., Deng, Y., Lee, K.-W., Millward, M., Grewal, J. S., Gadgeel, S. M., Sanborn, R. E., Hou, X., Wei, S., et al. (2023) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 12

1622P D-1553 in patients with KRAS G12C mutated advanced pancreatic cancer (pca)

Kondo, S., Yan, D., Ganju, V., Richardson, G., Hou, X., Shan, J., Liu, X., Zhang, Y., Xie, X., Xiang, Z., et al. (2023) · Annals of Oncology

Pancreatic and Hepatic Oncology ResearchProtein Kinase Regulation and GTPase Signaling

Cited by 6

Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer

Yamamoto, N., Yan, D., Ganju, V., Hou, X., Pan, H., Shan, J., Wang, L., Kim, S.-W., Richardson, G., Sanborn, R. E., et al. (2026) · British Journal of Cancer

Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and Treatment

Cited by 5

Abstract CT504: A phase 1 clinical trial to evaluate safety, tolerability, pharmacokinetics (PK) and efficacy of D-1553, a novel KRASG12C inhibitor, in patients with advanced or metastatic solid tumor harboring KRASG12C mutation

Price, T., Grewal, J., Abed, A., Moore, M., Yeh, Y.-M., Gadgeel, S., Richardson, G., Underhill, C., Ganju, V., Lee, K.-W., et al. (2022) · Cancer Research

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 3